ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,416.45
-0.09%
Dow Jones
39,872.99
0.17%
Gold vs US Dollar
2,419.02
-0.10%
Brent Oil
82.17
-0.33%
Bitcoin
69,973.26
-0.23%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Pharnext (ALPHA)

  7. Pharnext (ALPHA) News

Pharnext (ALPHA)

Pharnext
Date:
Sort by:
 Showing the most relevant articles for your search:EU:ALPHA
DateTimeSourceHeadlineSymbolCompany
01/11/202312:35GlobeNewswire Inc.International companies to host live webcasts at Deutsche Bank’s Depositary ReceiptsEU:ALPHAPharnext
16/05/202207:30GlobeNewswire Inc.De nouvelles données de l’essai en ouvert PLEO-CMT-FU montrent un bénéfice durable de PXT3003 chez les patients atteints de la maladie de Charcot-Marie-Tooth de type 1A après une durée totale de cinq ans d’essai cliniqueEU:ALPHAPharnext
16/05/202207:30GlobeNewswire Inc.New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial TimeEU:ALPHAPharnext
16/05/202207:30GlobeNewswire Inc.New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial TimeEU:ALPHAPharnext
28/04/202117:21GlobeNewswire Inc.Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with ...EU:ALPHAPharnext
28/04/202117:14GlobeNewswire Inc.Une analyse intermédiaire de l’étude de Phase III d’extension en ouvert en cours montre un benefice durable du traiteme...EU:ALPHAPharnext
02/01/201817:31Cercle FinancePharnext: un nouveau venu au conseil d'administrationEU:ALPHAPharnext
30/11/201706:38Cercle FinancePharnext: succès des analyses de l'essai PLEO-CMT.EU:ALPHAPharnext
26/06/201707:46Cercle FinanceCalendrier des sociétés sur 15 joursEU:ALPHAPharnext
20/12/201608:12Cercle FinancePharnext: fin du recrutement pour une étude de phase 3.EU:ALPHAPharnext
17/11/201611:25Cercle FinancePharnext: l'étude de phase 3 se poursuit.EU:ALPHAPharnext
18/07/201612:53Cercle FinancePharnext: sous son prix d'introduction pour ses débuts.EU:ALPHAPharnext
18/07/201612:23Dow Jones NewsECHO IPO: Pharnext lève 31 mln d'euros en s'introduisant sur AlternextEU:ALPHAPharnext
14/07/201608:43Cercle FinancePharnext: près de 31 millions d'euros levés grâce à l'IPO.EU:ALPHAPharnext
08/04/201011:58DPA AFX NachrichtenAKTIEN IM FOKUS: Griechische Banken unter Druck - Sorgen wegen FinanzkriseEU:ALPHAAlpha Bank A E
23/02/201015:37DPA AFX NachrichtenRating: Fitch stuft die vier größten griechischen Banken herabEU:ALPHAAlpha Bank A E
 Showing the most relevant articles for your search:EU:ALPHA

Your Recent History

BIBX
NESTETH
NEST
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved